

Valproate in children, young people and adults: summary of NICE guidance and safety advice

Valproate¹ is licensed for use in epilepsy and bipolar disorder. It is also used off-label for depression, neuropathic pain, dementia and migraine. It is associated with a significant risk of birth defects (including spina bifida and face and skull malformations) and developmental disorders in children born to women who take valproate during pregnancy.

Valproate interacts with a number of medicines, including other antiepileptic medicines, antipsychotics and antibiotics. See the [BNF](#), [BNF for Children](#) and relevant [summary of product characteristics](#) (SPCs) for more details. See also, the MHRA drug safety update [carbapenems: concomitant use with valproic acid not recommended](#).

Epilepsy²

NICE's guideline on [epilepsies](#) has recommendations on using valproate according to seizure type (see next page).

Bipolar disorder

NICE's guideline on [bipolar disorder](#) has recommendations on using valproate to manage mania or hypomania and bipolar depression in adults in secondary care (see next page).

Antenatal mental health

NICE's guideline on [antenatal and postnatal mental health](#) recommends that valproate should not be used for the acute or long-term treatment of a mental health problem in women of childbearing potential, planning a pregnancy, pregnant or considering breastfeeding.

Depression

NICE's guideline on [depression in adults](#) recommends that valproate should not be used routinely with an antidepressant.

Neuropathic pain

NICE's guideline on [neuropathic pain in adults in non-specialist settings](#) recommends that valproate should not be used unless advised by a specialist.

Dementia

NICE's guideline on [dementia](#) recommends that valproate should not be used to manage agitation or aggression in people with dementia, unless indicated for another condition.

Migraine

NICE's guideline on [headaches in over 12s](#) does not recommend valproate.

Women or girls of childbearing potential

Do not prescribe valproate for any condition, unless there is no other effective or tolerated treatment available, and only if the terms of the [pregnancy prevention programme](#) are met. See the 2018 MHRA safety advice on [valproate use by women and girls](#).

NICE's guideline on [bipolar disorder](#) recommends:

- If a woman or girl of childbearing potential is already taking valproate, advise her to gradually stop the medicine because of the risk of fetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy.
- The dose of valproate should be reduced gradually over at least 4 weeks to minimise the risk of relapse.

The [SPCs for valproate](#) advise:

- Valproate must be initiated and supervised by a specialist.
- The benefits and risks of treatment should be carefully reconsidered at regular treatment reviews.
- It should preferably be prescribed as monotherapy and at the lowest effective dose, if possible as a prolonged-release formulation.
- The daily dose should be divided into at least 2 single doses.

Stopping valproate: No woman or girl should stop taking valproate without first discussing it with their doctor ([MHRA safety advice](#)).

Women or girls who are pregnant or planning pregnancy

Epilepsy: Do not prescribe valproate, unless there is no other effective treatment available.

All other conditions: Do not prescribe valproate.

The [pregnancy prevention programme](#) advises:

- Women or girls who plan to become pregnant should be referred urgently to the specialist managing their condition. They should not stop contraception or valproate until advised to by their specialist.
- Women or girls with unplanned pregnancy should be urgently referred to a specialist and informed not to stop valproate before they are seen by the specialist.

The [SPCs for valproate](#) advise:

- All women or girls with valproate-exposed pregnancy, and their partners, should be referred to a specialist experienced in prenatal medicine for evaluation and counselling. See SPCs for details.

¹ 'Valproate' refers to 3 formulations of valproate available in the UK: sodium valproate, valproic acid and valproate semisodium. Both valproate semisodium and sodium valproate are metabolised to valproic acid, which is the pharmacologically active component. The UK marketing authorisation for the 3 formulations of valproate differ depending on the individual product. At the time of publication (March 2019), licensed indications for valproate are the treatment of epilepsy, and the treatment of acute mania and for continuation treatment in people who have had mania that has responded to treatment with valproate. See the individual SPCs for further information.

² Follow DVLA guidance on [epilepsy and driving](#) and MHRA advice on [antiepileptic drugs: switching between different manufacturers' products](#).

NICE recommendations on epilepsy

NICE's guideline on epilepsies has recommendations on using valproate for the following seizure types:

- [focal seizures](#)
- [newly diagnosed generalised tonic-clonic \(GTC\) seizures](#)
- [absence seizures](#)
- [myoclonic seizures](#)
- [tonic or atonic seizures](#)
- [Dravet syndrome](#)
- [Lennox-Gastaut syndrome](#)
- [benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome or late-onset childhood occipital epilepsy \(Gastaut type\)](#)
- [idiopathic generalised epilepsy \(IGE\)](#)
- [juvenile myoclonic epilepsy \(JME\)](#)
- [epilepsy with generalised tonic-clonic \(GTC\) seizures only](#)
- [childhood absence epilepsy, juvenile absence epilepsy or other absence epilepsy syndromes](#)

NICE recommendations on bipolar disorder

NICE's guideline on bipolar disorder makes recommendations on using valproate to manage:

- [mania or hypomania in adults in secondary care](#)
- [bipolar depression in adults in secondary care](#)
- [bipolar disorder in adults in the longer term in secondary care](#)

It also recommends that valproate should not be started in primary care to treat bipolar disorder:

- [managing bipolar disorder in primary care](#)

NICE quality standard on antenatal and postnatal mental health

NICE's quality standard on antenatal and postnatal mental health includes a quality statement on:

- [valproate](#)